InVasc Therapeutics announces initial closing of $3,150,000 in first institutional financing

NewsGuard 100/100 Score
Jul 9 2010

InVasc Therapeutics, Inc. today has had an initial closing of $3,150,000 in its first institutional financing. The investment was led by Trois I Investments Industriels Internationaux S.A., headquartered in Luxembourg.

“We welcome Trois I and our other investors”

"We welcome Trois I and our other investors," stated William Johnston, Ph.D., Chief Executive Officer of InVasc. "The funds raised will primarily be used to advance a Phase II trial for INV-144. The members of our new board will include Daniele Cardoso of Trois I, Larry Dillaha, the former EVP and Chief Medical Officer of Sciele Pharma, Bill Schaeffer, Chief Operating Officer of InVasc and me."

SOURCE InVasc Therapeutics, Inc.,

Posted in:

Tags: , , , , , ,

Comments (0)

Suggested Reading

CN Bio PhysioMimix Organ-on-a-Chip data supports Inipharm’s INI-822 for metabolic liver disease treatment now in clinical testing
Study reveals inflammation's role in long COVID's lingering effects
AMG 133 (maridebart cafraglutide) weight loss drug shows promise in early trial
Immune protein Ku70 key in fighting bowel cancer
Vaccines targeting chronic diseases show promise in combatting age-related conditions
Study suggests high levels of vitamin B3 breakdown products are linked to higher risk of mortality, heart attacks, and stroke
Study finds patients with long COVID exhibit complement dysregulation with signs of thromboinflammation
Revvity Signals Software unveils Signals Clinical solution to accelerate critical clinical trial insights and data-driven decisions

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Natural killer cells lead the charge in cancer treatment innovation